INBS CEO Harry Simeonidis is optimistic about the use of fun...
INBS CEO Harry Simeonidis is optimistic about the use of funds from the private placement, aiming to advance clinical trials for their Intelligent Fingerprinting Drug Screening System and broaden their market.
Press Release: Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3238Followers
0Following
8001Visitors
Follow